Reliance Global Group (EZRA) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue reached $3.23M, up 1% year-over-year; six-month revenue was $7.32M, up 3% year-over-year.
Net loss from continuing operations for Q2 2024 was $1.49M, a 62% improvement from Q2 2023.
Operating expenses decreased by 13% in Q2 2024 compared to Q2 2023, reflecting efficiency improvements.
The OneFirm strategy and integration of nine agencies supported organic growth, higher commission tiers, and cross-selling.
The company operates B2C and B2B InsurTech platforms, 5MinuteInsure.com and RELI Exchange, expanding its digital and agency partner footprint.
Financial highlights
Q2 2024 commission income was $3.23M, up 1% year-over-year; six-month revenue was $7.32M, up 3%.
Net loss for Q2 2024 was $1.49M, a 41% improvement from Q2 2023; six-month net loss was $6.84M, up from $2.84M in the prior year due to a $3.92M asset impairment.
AEBITDA loss for Q2 2024 was $178K (just under 6% of revenues); six-month AEBITDA loss was $252K.
Operating expenses for Q2 2024 decreased to $4.4M from $5M in Q2 2023.
Cash and restricted cash at June 30, 2024, totaled $2.82M; working capital was $0.6M.
Outlook and guidance
Spetner Associates acquisition expected to close in H2 2024, projected to double annual revenue to ~$28M and significantly boost EBITDA.
Real estate division to launch post-acquisition, aiming for accretive, cash flow-positive deals and portfolio diversification.
Enhanced capital structure expected to attract investors and support future growth initiatives.
Management plans continued expansion via acquisitions and organic growth, leveraging InsurTech platforms.
The company believes its financial position and ability to raise capital are sufficient for ongoing operations.
Latest events from Reliance Global Group
- Net loss improved to $1.4M as insurance growth and tech/life sciences investments advanced.EZRA
Q1 20268 May 2026 - All proposals passed, with leadership focused on growth and stockholder value.EZRA
AGM 20266 May 2026 - Strategic tech expansion, divestitures, and improved financials position for future growth.EZRA
Q4 20256 May 2026 - Strategic investment in Innervate Radiopharmaceuticals advances late-stage healthcare platform exposure.EZRA
Proxy filing4 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and major share issuance.EZRA
Proxy filing23 Mar 2026 - Shareholders will vote on director elections, equity plan expansion, and a $50M share issuance.EZRA
Proxy Filing12 Mar 2026 - Raising $5.3M for growth, tech, and digital assets amid dilution and Nasdaq compliance risks.EZRA
Registration Filing23 Jan 2026 - Q3 2024 delivered revenue growth, cost cuts, positive Adjusted EBITDA, and major M&A and tech moves.EZRA
Q3 202415 Jan 2026 - Revenue up 2%, net loss down 24%, and tech advances set stage for further growth.EZRA
Q4 202426 Dec 2025